HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Buchan, A. M Search for Related Content PubMed Articles by Buchan, A. M

Acute stroke treatment: the end of the first decade

Professor of Geratology and Honorary Consultant Neurologist, Oxford Acute Stroke Programme, Nuffield Department of Clinical Medicine, University of Oxford, Level 7, John Radcliffe Hospital, Oxford OX3 9DU, UK; alastair. buchan@ndm.ox.ac.uk

The first 150 words of the full text of this article appear below.

The year 2006 sees the end of the first decade of delivering intravenous thrombolysis for acute ischaemic stroke. Few other treatments have had to endure the scrutiny that tissue plasminogen activator (tPA) has been subjected to over that time, in part because of the real concerns of harming patients when treating them outside of the so-called NINDS box guidelines. However, part of the reluctance of physicians to take up this therapy is that it requires the re-engineering of everyday clinical practice. Unlike other stroke treatments, the press of time forces doctors to make rapid decisions while patients are examined and, crucially, imaged immediately on arrival at the hospital. So, what are the insights that these 10 years have given us? Has the disruption been worth it? What does the future hold?

The efficacy studies of intravenous thrombolysis have been well publicised and widely discussed, the most frequent concern being the . . . [Full text of this article]